Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells

Fitzmaurice, 2015, The global burden of cancer 2013, JAMA Oncol., 1, 505, 10.1001/jamaoncol.2015.0735 Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 Parcesepe, 2016, Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer, Gastroenterol. Res. Pract., 2016, 6261721, 10.1155/2016/6261721 Ribas, 2015, Adaptive immune resistance: how cancer protects from immune attack, Cancer Discov., 5, 915, 10.1158/2159-8290.CD-15-0563 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 Okazaki, 2007, PD-1 and PD-1 ligands: from discovery to clinical application, Int. Immunol., 19, 813, 10.1093/intimm/dxm057 Ishida, 1992, Induced expression of PD-1 a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J., 11, 3887, 10.1002/j.1460-2075.1992.tb05481.x Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med., 8, 793, 10.1038/nm730 Gentzler, 2016, Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors, Immunotherapy, 8, 583, 10.2217/imt-2015-0029 Gevensleben, 2016, The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer, Clin. Cancer Res., 22, 1969, 10.1158/1078-0432.CCR-15-2042 Moehler, 2016, Immunotherapy in gastrointestinal cancer: recent results: current studies and future perspectives, Eur. J. Cancer, 59, 160, 10.1016/j.ejca.2016.02.020 Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med., 192, 1027, 10.1084/jem.192.7.1027 Angelova, 2015, Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy, Genome Biol., 16, 64, 10.1186/s13059-015-0620-6 Massari, 2016, Magnitude of PD-1: PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis, Target Oncol., 11, 345, 10.1007/s11523-015-0396-3 Lee, 2016, Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma, Mod. Pathol., 10.1038/modpathol.2016.139 Lee, 2006, Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274), FEBS Lett., 580, 755, 10.1016/j.febslet.2005.12.093 Zhang, 2016, Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition, Oncogene Zhang, 2014, Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment, Prostate, 74, 869, 10.1002/pros.22805 Zhang, 2012, Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models, Cancer Res., 72, 2589, 10.1158/0008-5472.CAN-11-3795 Wu, 2009, A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17T cell responses, Nat. Med., 15, 1016, 10.1038/nm.2015 Ruddy, 2004, Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members, J. Biol. Chem., 279, 2559, 10.1074/jbc.M308809200 Cunningham, 2015, In vitro and in vivo model systems used in prostate cancer research, J. Biol. Methods, 2, 1, 10.14440/jbm.2015.63 Park, 2005, A distinct lineage of CD4T cells regulates tissue inflammation by producing interleukin 17, Nat. Immunol., 6, 1133, 10.1038/ni1261 Harrington, 2005, Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages, Nat. Immunol., 6, 1123, 10.1038/ni1254 Langrish, 2005, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J. Exp. Med., 201, 233, 10.1084/jem.20041257 Dunne, 2016, Enrichment of inflammatory IL-17 and TNF-alpha secreting CD4(+) T cells within colorectal tumors despite the presence of elevated CD39(+) T regulatory cells and increased expression of the immune checkpoint molecule, PD-1, Front Oncol., 6, 50, 10.3389/fonc.2016.00050 Sfanos, 2008, Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing, Clin. Cancer Res., 14, 3254, 10.1158/1078-0432.CCR-07-5164 Yang, 2017, Posttranscriptional control of PD-L1 expression by 17beta-estradiol via PI3K/Akt signaling pathway in ERalpha-positive cancer cell lines, Int. J. Gynecol. Cancer, 27, 196, 10.1097/IGC.0000000000000875 Chen, 2014, AZD5363 inhibits inflammatory synergy between interleukin-17 and insulin/insulin-like growth factor 1, Front. Oncol., 4, 343, 10.3389/fonc.2014.00343 Muthumani, 2011, HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8T cells, J. Immunol., 187, 2932, 10.4049/jimmunol.1100594 Chen, 2006, Triptolide inhibits B7-H1 expression on proinflammatory factor activated renal tubular epithelial cells by decreasing NF-kappaB transcription, Mol. Immunol., 43, 1088, 10.1016/j.molimm.2005.07.026 Gowrishankar, 2015, Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB, PLoS One, 10, e0123410, 10.1371/journal.pone.0123410 Huang, 2013, NF-kappaB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment, PLoS One, 8, e61602, 10.1371/journal.pone.0061602 Xiong, 2014, IL-12 regulates B7-H1 expression in ovarian cancer-associated macrophages by effects on NF-kappaB signalling, Asian Pac. J. Cancer Prev., 15, 5767, 10.7314/APJCP.2014.15.14.5767 Sumimoto, 2006, The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells, J. Exp. Med., 203, 1651, 10.1084/jem.20051848 Chen, 2015, Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation, J. Thorac. Oncol., 10, 910, 10.1097/JTO.0000000000000500 Jiang, 2013, The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition, Clin. Cancer Res., 19, 598, 10.1158/1078-0432.CCR-12-2731 Song, 2013, PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer, PLoS One, 8, e65821, 10.1371/journal.pone.0065821 Mittendorf, 2014, PD-L1 expression in triple-negative breast cancer, Cancer Immunol. Res., 2, 361, 10.1158/2326-6066.CIR-13-0127